5 mg Rosuvastatin will be orally administered once daily for two years. Target LDL-C levels are 80 mg/dL for primary prevention, and 70 mg/dL for secondary prevention. If these levels are not achieve
Sponsors
Japan Atherosclerosis Regressive Treatment Study Group
Conditions
Hypercholesterolemia
Unknown Phase
Justification for Atherosclerosis Regression Treatment
Active, not recruitingJPRN-UMIN000001174
Start: 2008-06-01Target: 400Updated: 2026-06-29
Justification for Atherosclerosis Regression Treatment [JART Extension Study]
Active, not recruitingJPRN-UMIN000005774
Start: 2008-06-01Target: 400Updated: 2026-06-29